Free Trial

Wealth Enhancement Advisory Services LLC Takes $719,000 Position in GRAIL, Inc. (NASDAQ:GRAL)

GRAIL logo with Medical background

Wealth Enhancement Advisory Services LLC acquired a new stake in shares of GRAIL, Inc. (NASDAQ:GRAL - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 28,163 shares of the company's stock, valued at approximately $719,000. Wealth Enhancement Advisory Services LLC owned about 0.08% of GRAIL as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of GRAL. Lindbrook Capital LLC purchased a new stake in GRAIL in the fourth quarter worth about $28,000. State of Tennessee Department of Treasury purchased a new stake in GRAIL in the fourth quarter worth about $28,000. Caldwell Sutter Capital Inc. purchased a new stake in GRAIL in the first quarter worth about $28,000. Sterling Capital Management LLC purchased a new stake in GRAIL in the fourth quarter worth about $29,000. Finally, Wellington Shields Capital Management LLC purchased a new stake in GRAIL in the fourth quarter worth about $33,000.

Insider Transactions at GRAIL

In related news, major shareholder Chun R. Ding sold 339,800 shares of the stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $49.53, for a total transaction of $16,830,294.00. Following the completion of the transaction, the insider directly owned 3,305,055 shares of the company's stock, valued at approximately $163,699,374.15. This represents a 9.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, President Joshua J. Ofman sold 48,213 shares of the stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $33.93, for a total value of $1,635,867.09. Following the transaction, the president directly owned 511,460 shares of the company's stock, valued at approximately $17,353,837.80. The trade was a 8.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 532,890 shares of company stock valued at $23,556,972 in the last ninety days.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on GRAL shares. Morgan Stanley upped their price objective on GRAIL from $16.00 to $20.00 and gave the stock an "equal weight" rating in a research note on Tuesday, March 18th. Canaccord Genuity Group upped their price objective on GRAIL from $32.00 to $43.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th.

Check Out Our Latest Stock Analysis on GRAL

GRAIL Price Performance

Shares of NASDAQ GRAL traded down $0.75 during mid-day trading on Friday, reaching $46.81. The company's stock had a trading volume of 1,042,680 shares, compared to its average volume of 1,188,194. The firm has a market capitalization of $1.68 billion and a PE ratio of -0.77. The stock has a fifty day moving average of $40.79 and a two-hundred day moving average of $32.93. GRAIL, Inc. has a 52 week low of $12.33 and a 52 week high of $63.99.

GRAIL (NASDAQ:GRAL - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($3.10) EPS for the quarter, beating analysts' consensus estimates of ($4.03) by $0.93. GRAIL had a negative return on equity of 17.99% and a negative net margin of 1,464.53%. The company had revenue of $31.84 million during the quarter, compared to analyst estimates of $35.80 million. Analysts anticipate that GRAIL, Inc. will post -15.15 EPS for the current fiscal year.

GRAIL Profile

(Free Report)

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.

See Also

Institutional Ownership by Quarter for GRAIL (NASDAQ:GRAL)

Should You Invest $1,000 in GRAIL Right Now?

Before you consider GRAIL, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GRAIL wasn't on the list.

While GRAIL currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines